Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Management of myelodysplastic syndromes: 2008 update Scott BL; Estey EOncology (Williston Park) 2008[Nov]; 22 (12): 1344-52Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic disorders characterized by low blood counts and a tendency to progress to acute myeloid leukemia. Treatment options have increased over the past 10 years, and many new agents are currently being investigated. In this article, we review the diagnosis of MDS, prognostic systems, and treatment options, including supportive care, erythropoiesis-stimulating agents, antithymocyte globulin, lenalidomide, azacitidine, decitabine, intensive chemotherapy, and hematopoietic cell transplantation.|*Hematopoietic Stem Cell Transplantation[MESH]|Antilymphocyte Serum/therapeutic use[MESH]|Antineoplastic Combined Chemotherapy Protocols/*therapeutic use[MESH]|Azacitidine/administration & dosage/analogs & derivatives[MESH]|Clinical Trials as Topic[MESH]|Decitabine[MESH]|Disease-Free Survival[MESH]|Granulocyte Colony-Stimulating Factor/therapeutic use[MESH]|Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use[MESH]|Hematinics/adverse effects/*therapeutic use[MESH]|Humans[MESH]|Immunologic Factors/therapeutic use[MESH]|Iron Chelating Agents/*therapeutic use[MESH]|Lenalidomide[MESH]|Myelodysplastic Syndromes/*diagnosis/drug therapy/*therapy[MESH]|Survival Analysis[MESH]|Thalidomide/administration & dosage/analogs & derivatives[MESH]|Treatment Outcome[MESH] |